Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-11-08

FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for AMYVID (florbetapir F-18) by Eli Lilly, updating its use as an imaging agent to estimate beta-amyloid neuritic plaqu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMYVID (Florbetapir F-18)

Snippet

SUPPL AP for AMYVID (FLORBETAPIR F 18)